NGR peptide Trifluoroacetate

Research use only, not for human use.

NGR peptide Trifluoroacetate containing the asparagine-glycine-arginine (NGR) motif is recognized by CD13/aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in tumor neovasculature.

NGR peptide Trifluoroacetate containing the asparagine-glycine-arginine (NGR) motif is recognized by CD13/aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in tumor neovasculature.(In Vitro):NGR peptide can selectively bind to APN/CD13 either immune-captured or expressed on the surface of cells, the receptor of the tumor-homing NGR peptide was suspected to be APN/CD13. The NGR peptide is reported to have the greatest tumor selectivity. An anti-cancer drug Doxorubicin (DOX) coupled to an NGR peptide displays enhanced anti-tumor effects with even lower toxicity than the free drug itself.(In Vivo):NGR peptide imaging in vivo not only provides more insight into NGR’s targeting process, including bio-distribution and pharmacokinetics, but also reveals angiogenic activities related to tumor progression and malignancy.

Others

Other Targets

CD13/aminopeptidase N (APN) receptor

——

——

--

722.7

C22H37F3N10O10S2

>98% (HPLC)

H2O : ≥ 100 mg/mL (138.37 mM)

——

(-20℃)

With Ice Pack

≥ 2 years